Search

everythinglearnresearchcommunity

for

Search:↓

Oral DHT blockers like finasteride are preferred for their ease of use, effectiveness, and long-term safety data, while topical treatments like RU58841 lack extensive safety data and can be more cumbersome to apply. Oral treatments are generally considered more effective and convenient despite potential side effects.

Concerns about France potentially banning finasteride and dutasteride due to supposed side effects, though no solid evidence supports this action. Users believe a ban is unlikely and discuss ways to obtain the treatments if it occurs.

The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.

The conversation is about finding a safe carrier for topical antiandrogens like finasteride, kx-826, RU58841, and dutasteride to minimize systemic absorption and side effects. The user experiences side effects from these treatments and is seeking advice on carriers that reduce these effects.

Hair loss discussion includes finasteride intolerance and questioning if Pyrilutamide is an alternative. Pyrilutamide not commercially available, but may be tolerable if approved since it's not a 5aR inhibitor.

The user experienced sensitivity and side effects from finasteride and Saw Palmetto, leading to swollen and sensitive breasts, and decided to stop finasteride after two weeks. They are now trying Saw Palmetto, Biotin, and Ashwagandha, while others in the conversation discuss their own experiences with hair loss treatments like minoxidil and finasteride.

User on fin, minox, and ketoconazole seeks to add another topical anti-androgen. Hierarchy of effectiveness: 1. RU55841, 2. Fluridil - Eucapil, 3. CB-03-01 - Breezula, 4. Ketoconazole; alfatradiol suggested as addition.

RU58841 cured seborrheic dermatitis, oily scalp, dandruff, and scalp pain, improving hair health when combined with Minoxidil. Another user noted diet impacts their seborrheic dermatitis and that finasteride hasn't changed their condition.

RU58841 is being mixed with Minoxidil solution, but concerns arise about water causing instability. Mixing with water may lead to hydrolysis, potentially reducing effectiveness.

The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.

A user is considering quitting RU58841 after using it for over three years alongside Dutasteride and Oral Minoxidil, and is concerned about potential hair loss. Other users share mixed opinions on RU58841's effectiveness, with some suggesting continued use of other treatments like Dutasteride and Minoxidil.

A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.

Medication caused hair loss, which stopped after discontinuing the drugs, but hair hasn't regrown yet. The user is considering seeing a doctor for further advice and possibly using biotin supplements.

A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.

Finasteride users cannot donate blood due to potential risks to pregnant women, requiring a one-month cessation before donating. Dutasteride requires a six-month deferral, and topical applications are not restricted.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

The user has been on finasteride for over four years without noticeable results and recently added dutasteride and RU58841, but continues to experience hair loss. They are considering stopping all medications due to lack of effectiveness and side effects like extremely dry eyes from dutasteride.

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

An 18-year-old is frustrated with a dermatologist who prescribed shampoos and Betnovate instead of Minoxidil and Finasteride for hair loss and seborrheic dermatitis. The user feels misled and is considering giving up on dermatologists.

Minoxidil's effectiveness varies due to genetic differences in the SULT1A1 enzyme, affecting how well it converts to its active form, minoxidil sulfate. Hyper-responders may experience rapid hair growth and increased side effects, such as pericardial effusion, even at low doses.

The user switched from Pyrilutamide to RU58841, changed their Minoxidil solution, and continued using low-dose Finasteride, derma rolling, and specific shampoo. They asked others about their plans after Pyrilutamide's disappointing results.

The conversation discusses using aromatase inhibitors with dutasteride or finasteride for hair loss, which can prevent testosterone from turning into estrogen but may lead to increased DHT and potentially make finasteride less effective. There's concern about proper dosing and side effects like gynecomastia and emotional changes.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

A transwoman is struggling with hair loss despite using hormones, dutasteride, and Abiraterone, and is considering making her own treatments due to difficulty accessing them. She has also tried Eucapil and regularly uses Nizoral shampoo.

The conversation is about adding crushed bicalutamide or spironolactone to a topical mix with finasteride and minoxidil to suppress testosterone in hair follicles, similar to what RU58841 does. The user cannot obtain RU58841 in their country and is seeking advice on this alternative approach for hair loss treatment.

A user in France is frustrated because three dermatologists refused to prescribe finasteride for their hair loss, suggesting it's not androgenetic alopecia (AGA) and offering expensive vitamin treatments instead. Other users suggest buying hair loss treatments like minoxidil and finasteride from various online pharmacies and considering a gender-affirming care physician for more understanding treatment options.

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.